

Mentice Opens Strategic Hub for Software Development

The newly established Mentice Spain S.L. office in the heart of Barcelona, Spain, will serve as an additional hub for Mentice group's software development, with an initial focus on the recently acquired, CE-marked Ankyras® intracranial aneurysm decision support solution.

The new regional office will focus on advancing simulation-based decision-support solutions in clinical practice as part of Mentice's strategy to expand its business vertically within the Image-Guided Interventional Therapies (IGIT) market.

Mentice AB (STO: MNTC) today announced the opening of a new regional office in Barcelona, Spain. Setting up the new company is part of the integration work following last year's acquisition of Ankyras® - a solution that provides simulated assessment for the planning of neurovascular flow diversion in the treatment of intracranial aneurysms. The new company, Mentice Spain S.L., will focus on research, development, and the manufacturing of medical software products.

With the introduction of increasingly complex procedures and devices, such as flow diverters, in the interventional market over the last few years, the demand for solutions that support device manufacturers with optimal design and physicians in making informed treatment choices has increased. Also, the rapid growth of image analysis and AI technology in medical imaging has opened the door to new approaches for effectively addressing this need. Barcelona has proven to be a strategic location for innovation and a wealth of software development resources, complementing Mentice R&D Head Quarter in Gothenburg, Sweden.

"The establishment of Mentice Spain S.L. is a huge step for Mentice on our journey to pivot from a simulation company to a provider of clinical performance solutions for procedural and device adoption," said Edward Fält, VP of M&A and Strategy at Mentice. "We now have the technology and regulatory tools we need to develop medical imaging solutions and to integrate closely into the clinical workflow, with clear synergies for training and rollout of new interventional devices. Manufacturers and hospitals will now, for the first time, have access to a unique set of solutions covering both device design, training, and planning, all from a single vendor."

In the mid-term, Mentice plans to further integrate the clinical-decision support application within the current solution portfolio, including virtual, physiological, and cloud simulation. This allows users to build personalized procedural and case data libraries to repurpose application scenarios.

To learn more about Ankyras - Braided Device Sizing Support Application, visit, mentice.com/ankyras

Mentice subsidiaries and partners will distribute the medical software products developed and manufactured by Mentice Spain S.L. in approved markets.

For more information, please contact:

Edward Fält, VP M&A and Strategy, Mentice

E-post: edward.faelt@mentice.com

Mobile +46 709 73 00 63

About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

Attachments

[Mentice Opens Strategic Hub for Software Development](#)